SPRED1

Across TCGA pan-cancer cohorts, SPRED1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SPRED1 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SPRED1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPRED1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where SPRED1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.577	0.894	.002	22	view →
HNSC	DFS	Tertile	All	0.302	0.870	.024	16	view →
LUAD	DFS	Median	III,IV	0.553	0.928	.011	13	view →
OV	DFS	Tertile	All	0.624	1.000	.049	8	view →
PDAC	DFS	Tertile	II,III,IV	0.202	0.600	.024	5	view →
UCEC	DFS	Median	II,III,IV	0.141	0.803	.038	4	view →
GBM	OS	Median	All	0.974	0.735	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SPRED1–LSCC (DFS)

Open the LSCC breakdown →